MEDIVIR AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.24 SEK | +6.23% |
|
+21.35% | +13.68% |
| Apr. 25 | Medivir Gets Two US FDA Designations for MIV-711 | MT |
| Mar. 21 | Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024. | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 301.2 | 201.5 | 624.1 | 551.7 | 159.1 | 363 | - | - |
| Enterprise Value (EV) 1 | 210.5 | 131.5 | 402.9 | 434.3 | -10.48 | 268.3 | 305 | 297 |
| P/E ratio | -2.44 x | -4.74 x | -9.33 x | -6.23 x | -1.93 x | -3.58 x | -2.56 x | -2.35 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 41.8 x | 5.11 x | 17.5 x | 89 x | 17.7 x | 13.6 x | 6.96 x | 35.1 x |
| EV / Revenue | 29.2 x | 3.34 x | 11.3 x | 70 x | -1.16 x | 10 x | 5.85 x | 28.7 x |
| EV / EBITDA | -1.77 x | -3.42 x | -6.77 x | -5.12 x | 0.12 x | -3.58 x | -8.13 x | -2.45 x |
| EV / FCF | -1.41 x | -2.07 x | -8.27 x | -4.25 x | 0.17 x | -3.83 x | -1.77 x | -1.52 x |
| FCF Yield | -71.1% | -48.3% | -12.1% | -23.5% | 572% | -26.1% | -56.4% | -65.7% |
| Price to Book | 1.63 x | 1.42 x | 2.22 x | 2.86 x | 0.79 x | 1.23 x | 2.95 x | 2.84 x |
| Nbr of stocks (in thousands) | 24,288 | 24,276 | 55,724 | 55,724 | 55,830 | 112,042 | - | - |
| Reference price 2 | 12.40 | 8.300 | 11.20 | 9.900 | 2.850 | 3.240 | 3.240 | 3.240 |
| Announcement Date | 2/13/20 | 2/26/21 | 2/15/22 | 2/15/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.2 | 39.4 | 35.7 | 6.2 | 9 | 26.75 | 52.18 | 10.35 |
| EBITDA 1 | -118.9 | -38.5 | -59.5 | -84.8 | -88.7 | -74.95 | -37.5 | -121.3 |
| EBIT 1 | -126 | -42.9 | -62.1 | -87.4 | -91.4 | -96.47 | -93.13 | -154.8 |
| Operating Margin | -1,750% | -108.88% | -173.95% | -1,409.68% | -1,015.56% | -360.64% | -178.49% | -1,495.96% |
| Earnings before Tax (EBT) 1 | -123.3 | -42.6 | -62.6 | -88.8 | -89.3 | -96.4 | -93.05 | -154.8 |
| Net income 1 | -123.4 | -42.6 | -63.1 | -88.8 | -89.3 | -96.4 | -93.05 | -154.8 |
| Net margin | -1,713.89% | -108.12% | -176.75% | -1,432.26% | -992.22% | -360.36% | -178.34% | -1,495.23% |
| EPS 2 | -5.080 | -1.750 | -1.200 | -1.590 | -1.480 | -0.9050 | -1.267 | -1.377 |
| Free Cash Flow 1 | -149.7 | -63.5 | -48.7 | -102.2 | -60 | -70 | -172 | -195 |
| FCF margin | -2,079.04% | -161.17% | -136.41% | -1,648.39% | -666.67% | -261.68% | -329.66% | -1,884.06% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/13/20 | 2/26/21 | 2/15/22 | 2/15/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.4 | 18.8 | 1.7 | 15.3 | 0.9 | 0.9 | 1.8 | 2 | 2.5 | 0.8 | 2.6 | 3.3 | 1 | 4.7 | 1.9 | 2.1 | 4 | 3.66 | 3.84 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | - | -22.1 | - | -14.6 | -18.7 | - | - | - | -24.1 | -20.8 | -20.3 | -17.1 | -37.3 | -16.4 | -16.7 |
| Operating Margin | - | - | - | - | - | -2,455.56% | - | -730% | -748% | - | - | - | -2,410% | -442.55% | -1,068.42% | -814.29% | -932.5% | -448.09% | -434.9% |
| Earnings before Tax (EBT) 1 | -36.1 | -25.4 | -12.8 | -24.3 | -32.7 | -23.1 | -55.9 | -14.8 | -18.1 | -18.9 | -26.6 | -45.5 | -23.6 | -20.3 | -20.2 | -17 | -37.1 | -16.4 | -16.6 |
| Net income 1 | -36.1 | -25.5 | -13.3 | -24.3 | -32.7 | -23.1 | -55.9 | -14.8 | -18.1 | -18.9 | -26.6 | -45.5 | -23.6 | -20.3 | -20.2 | -17 | -37.1 | -16.4 | -16.6 |
| Net margin | -316.67% | -135.64% | -782.35% | -158.82% | -3,633.33% | -2,566.67% | -3,105.56% | -740% | -724% | -2,362.5% | -1,023.08% | -1,378.79% | -2,360% | -431.91% | -1,063.16% | -809.52% | -927.5% | -448.09% | -432.29% |
| EPS 2 | -1.490 | -0.5700 | -0.2600 | -0.4400 | -0.5900 | -0.4200 | -1.000 | -0.2700 | -0.3200 | -0.3400 | -0.4700 | -0.8100 | -0.4200 | -0.2800 | -0.2400 | -0.2000 | -0.4400 | -0.1800 | -0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/20/20 | 8/19/21 | 11/3/21 | 2/15/22 | 4/28/22 | 8/19/22 | 8/19/22 | 11/3/22 | 2/15/23 | 4/27/23 | 8/18/23 | 8/18/23 | 10/27/23 | 2/15/24 | - | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 90.6 | 70 | 221 | 117 | 170 | 94.7 | 58 | 66 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -150 | -63.5 | -48.7 | -102 | -60 | -70 | -172 | -195 |
| ROE (net income / shareholders' equity) | -50.2% | -26.1% | -29.8% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 7.590 | 5.840 | 5.040 | 3.460 | 3.610 | 2.640 | 1.100 | 1.140 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.44 | 5.4 | - | 0.4 | 0.3 | 1 | 1 | 3 |
| Capex / Sales | 19.94% | 13.71% | - | 6.45% | 3.33% | 3.74% | 1.92% | 28.99% |
| Announcement Date | 2/13/20 | 2/26/21 | 2/15/22 | 2/15/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.24
SEK
Average target price
20.55
SEK
Spread / Average Target
+534.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.68% | 33.11M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MVIR B Stock
- Financials Medivir AB
